C.W. Downer & Co. Assists Cornerstone Pharmaceuticals, Inc., with $6m Capital Raise
Boston, January 26, 2010 - Cornerstone Pharmaceuticals, Inc. announced that is has closed a Series B4 preferred investment round totaling $6,175,000. The funds were raised from a private investor group and will be used to further develop Cornerstone’s promising cancer drug (CPI-613) and to continue research efforts into its two distinct technology platforms; Altered Energy Metabolism-Directed (AEMD) and Emulsiphan.
Privately-held, with offices & laboratories in New Jersey and New York, Cornerstone Pharmaceuticals is uniquely focused on developing innovative cancer therapies that target similarities in metabolic pathways between multiple varieties of solid tumor cancers, including pancreatic cancer. CPI-613 was named one of the 10 most interesting oncology projects in 2009 by Windhover Information, a provider of analysis of the healthcare industry for over 25 years.
Ruta Laukien, Director, and Tim Sullivan, Advisory Director, with C.W. Downer & Co., assisted Cornerstone Pharmaceuticals with the fund raising effort.
About Cornerstone Pharmaceuticals, Inc.
Cornerstone Pharmaceuticals, Inc. is a privately held pharmaceutical company singularly focused on the discovery and development of innovative cancer therapies that exploit the metabolic pathways that are common to different cancer types but different from normal cells and tissues. This unique approach, i.e. understanding and addressing what is similar to multiple cancer types rather than the differences between each, offers a significant opportunity to make a profound impact on the clinical treatment of a variety of cancers. For further information, please call (212) 843-8073 or log onto http://www.cornerstonepharma.com.
About C.W. Downer & Co.
C.W. Downer & Co. is an independent, global investment bank offering middle-market clients a high level of personal attention coupled with more than 30 years of international execution experience. We provide insight, not just information. We generate value, not just transactions. With offices in six countries and on four continents, we consistently identify the most appropriate strategic buyer and uncover “hidden” acquisition targets. C.W. Downer & Co. delivers the reach of a bulge-bracket investment bank with the senior level focus of a boutique. For more information, visit http://www.cwdowner.com.
For Further Information:
Ruta Laukien, Director
This e-mail address is being protected from spambots. You need JavaScript enabled to view it
Patti Allan, Marketing Director
This e-mail address is being protected from spambots. You need JavaScript enabled to view it
C.W. Downer & Co.
+1 617 482 6200
